<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068263</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0319</org_study_id>
    <secondary_id>CDR0000316246</secondary_id>
    <nct_id>NCT00068263</nct_id>
  </id_info>
  <brief_title>3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection</brief_title>
  <official_title>A Phase I/II Trial to Evaluate Three Dimensional Conformal Radiation Therapy (3D-CRT) Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: 3-dimensional conformal radiation therapy delivers a high dose of radiation&#xD;
      directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of 3-dimensional conformal radiation&#xD;
      therapy in treating women who have undergone lumpectomy and axillary node dissection for&#xD;
      stage I or stage II breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the technical feasibility and reproducibility of three-dimensional conformal&#xD;
           radiotherapy confined to the region of the lumpectomy cavity in women with stage I or II&#xD;
           breast cancer.&#xD;
&#xD;
        -  Determine the cosmetic results in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the complication rates in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the local control rate in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo three-dimensional conformal radiotherapy twice daily for 5 days beginning&#xD;
      within 8 weeks after surgery.&#xD;
&#xD;
      Patients are followed at 6 weeks, every 3 months for 1 year, every 4 months for 1 year, every&#xD;
      6 months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-46 patients will be accrued for this study within 6.3 to&#xD;
      15.3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Stage I or II (T1, N0; T1, N1; T2, N0; or T2, N1)&#xD;
&#xD;
               -  Unifocal disease (single focus that can be encompassed by one lumpectomy)&#xD;
&#xD;
               -  The following histologies are eligible:&#xD;
&#xD;
                    -  Invasive ductal&#xD;
&#xD;
                    -  Medullary&#xD;
&#xD;
                    -  Papillary&#xD;
&#xD;
                    -  Colloid (mucinous)&#xD;
&#xD;
                    -  Tubular&#xD;
&#xD;
          -  No invasive or extensive in situ lobular carcinoma or pure ductal carcinoma in situ&#xD;
             (DCIS)&#xD;
&#xD;
          -  No nonepithelial breast malignancies such as sarcoma or lymphoma&#xD;
&#xD;
          -  Previously treated with lumpectomy of a lesion no greater than 3 cm and axillary&#xD;
             dissection of at least 6 lymph nodes or a sentinel node biopsy&#xD;
&#xD;
               -  Six surgical clips in place delineating the margins of the tylectomy cavity&#xD;
&#xD;
               -  Negative, inked histologic margins of lumpectomy (greater than 2 mm) OR&#xD;
                  re-excision specimen available for confirmation&#xD;
&#xD;
               -  Negative mammography post-lumpectomy or post-excision if malignancy-associated&#xD;
                  microcalcifications were initially present&#xD;
&#xD;
               -  No prior lumpectomy so extensive that the cosmetic result is low or poor prior to&#xD;
                  radiotherapy&#xD;
&#xD;
          -  No more than 3 positive axillary nodes&#xD;
&#xD;
          -  No proven multicentric carcinoma (tumors in different quadrants of the breast or tumor&#xD;
             separated by at least 4 cm) with other clinically or radiographically suspicious areas&#xD;
             in the ipsilateral breast unless negative by biopsy&#xD;
&#xD;
          -  No palpable or radiographically suspicious contralateral axillary, supraclavicular,&#xD;
             infraclavicular, or internal mammary nodes unless nodes are histologically negative&#xD;
&#xD;
          -  No extensive intraductal carcinoma, indicated by one of the following according to the&#xD;
             Harvard definition:&#xD;
&#xD;
               -  More than 25 % of invasive tumor is DCIS and DCIS is in adjacent breast tissue&#xD;
&#xD;
               -  Intraductal carcinoma with microinvasion&#xD;
&#xD;
          -  No previously treated contralateral breast cancer or synchronous ipsilateral breast&#xD;
             cancer&#xD;
&#xD;
          -  No evidence of suspicious microcalcifications&#xD;
&#xD;
          -  No Paget's disease of the nipple&#xD;
&#xD;
          -  No skin involvement by disease, regardless of tumor size&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 2 years&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Technically suitable for breast radiotherapy&#xD;
&#xD;
          -  No collagenous diseases (e.g., systemic lupus erythematosus, scleroderma, or&#xD;
             dermatomyositis)&#xD;
&#xD;
          -  No other medical condition that would limit life expectancy&#xD;
&#xD;
          -  No psychiatric or addictive disorders that would preclude giving informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy during and for at least 2 weeks after completion of study&#xD;
             therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent anastrozole or tamoxifen allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for the current malignancy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior nonhormonal therapy for the current malignancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Vicini, MD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>William Beaumont Hospital - Royal Oak Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foundation for Cancer Research and Education</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vicini F, Winter K, Wong J, Pass H, Rabinovitch R, Chafe S, Arthur D, Petersen I, White J, McCormick B. Initial efficacy results of RTOG 0319: three-dimensional conformal radiation therapy (3D-CRT) confined to the region of the lumpectomy cavity for stage I/ II breast carcinoma. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1120-7. doi: 10.1016/j.ijrobp.2009.06.067. Epub 2009 Nov 10.</citation>
    <PMID>19910132</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicini F, Winter K, Straube W, Wong J, Pass H, Rabinovitch R, Chafe S, Arthur D, Petersen I, McCormick B. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1531-7. Epub 2005 Sep 29.</citation>
    <PMID>16198508</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>December 30, 2016</last_update_submitted>
  <last_update_submitted_qc>December 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

